Possibility of Real-Time Risk Assessment of Acute Upper Gastrointestinal Bleeding by Using TRI (TIMI Risk Index) Model
DOI:
https://doi.org/10.46966/msjar.v6i4.334Keywords:
TRI, TIMI risk index, Rockall score, upper gastrointestinal bleeding, myocardial infarctionAbstract
Purpose: The purpose of this study is to evaluate the predictive value of TRI(Thrombolysis in myocardial infarction risk index) in predicting UGIB(upper gastrointestinal bleeding), by comparing it to Rockall scores. Methods: We retrospectively studied 583 patients who admitted with the diagnosis of UGIB. Based on the recorded data, we compared AUCs(area under curves) of TRI and Rockall scores for rebleeding and death. Rebleeding rates and mortalities of all risk groups of TRI were obtained to check up the difference significances between neighboring groups. Results: AUC of TRI for rebleeding was 0.599, which was lower than AUCs of clinical and completed Rockall scores-0.655, 0.696. AUC of TRI for death was 0.741, which was also lower than AUCs of clinical and completed Rockall scores-0.838, 0.846. Rebleeding rates did not increase correlatively with the step-up of the risk grades of TRI. Mortality rates were 2.9%, 6.3%, 17.2%, 46.7%, 57.1%, respectively in 5 risk grades of TRI with increasing tendency by grade step-up, however, there were significant differences between rebleeding rates of low(10-<30) and moderate(30-60) risk groups, and between moderate and high(>60-80) risk groups(P=0.00017, 0.01763 respectively), but not between lowest(<10) and low risk groups, and between high and highest(>80) risk groups(P=0.41, not applicable respectively). Conclusion: Predictive value of TRI to forecast the outcomes of acute upper gastrointestinal bleeding is lower than Rockall scores. However, TRI is useful to predict UGIB mortality quickly, since this score shows significant risk stratification for mortality rate when divided into 3 risk groups-low(<30), moderate(30-60), and high risk group(>60).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sin-Hyok Jong, Song-Hwan Kim, Nam-Hun Jong, Hyo-Guk Pak, Hye-Sung Kim, Nam Yu, Dong-Hui Jo, Jong-Chol Kang

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















